2003
DOI: 10.1210/jc.2001-011428
|View full text |Cite
|
Sign up to set email alerts
|

Autosomal Dominant Hyperostosis/Osteosclerosis with High Serum Alkaline Phosphatase Activity

Abstract: We studied eight affected and four unaffected individuals from a Colombian family with autosomal dominant diffuse high bone density. Affected individuals have normal, proportional height and high serum alkaline phosphatase activity. Radiographically, affected members exhibit generalized, symmetrically diffuse endosteal hyperostosis of the long bones and skull with narrow medullary cavities and loss of the diploë, respectively. There is no periosteal reaction or decreased hematopoiesis. Furthermore, osteosclero… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2005
2005
2023
2023

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(2 citation statements)
references
References 22 publications
0
2
0
Order By: Relevance
“…In 2003, some individuals diagnosed with these disorders were discovered to carry gain‐of‐function mutations in LRP5 , (2,4) suggesting a shared genetic etiology for these high bone mass conditions. A Columbian kindred with autosomal dominant endosteal hyperostosis had normal sequence for LRP5 exon 3, but exons 2 and 4 were not studied, (29) so LRP5 gain‐of‐function remains possible. Our patient's disorder is consistent with Worth disease and was found to be caused by a novel missense mutation in exon 2 of LRP5 .…”
Section: Discussionmentioning
confidence: 99%
“…In 2003, some individuals diagnosed with these disorders were discovered to carry gain‐of‐function mutations in LRP5 , (2,4) suggesting a shared genetic etiology for these high bone mass conditions. A Columbian kindred with autosomal dominant endosteal hyperostosis had normal sequence for LRP5 exon 3, but exons 2 and 4 were not studied, (29) so LRP5 gain‐of‐function remains possible. Our patient's disorder is consistent with Worth disease and was found to be caused by a novel missense mutation in exon 2 of LRP5 .…”
Section: Discussionmentioning
confidence: 99%
“…Most patients with LRP5 activating mutations had normal ALP (15/17), P1NP (3/6) and β-CTX (10/15) levels. Compared with control group with normal bone mass, there was no significant difference in the levels of bone formation markers: ALP and P1NP, while the bone resorption biomarker β-CTX was decreased or normal (Frost et al 2003 ; Hernandez-Cassis et al 2003 ). ADO I is in autosomal dominant inheritance.…”
Section: Literature Review and Analysismentioning
confidence: 99%